Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker KYNB · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT06842498 · Metastatic Castration-Resistant Prostate Cancer FG-3246 | KYNB Kyntra Bio | Phase 2 | Recruiting | 75 | Mar 31, 2028 | Registry ↗ |
| Jul 23, 2026 | A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Parti… NCT07722988 · Myelodysplastic Syndromes Roxadustat, Placebo | KYNB Kyntra Bio | Phase 3 | Not yet recruiting | 201 | Sep 2030 | Registry ↗ |
| Nov 5, 2024 | Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Che… NCT03941093 · Pancreatic Cancer Non-resectable Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab +… | KYNB Kyntra Bio | Phase 3 | Completed | 284 | Jun 11, 2024 | Registry ↗ |
| Sep 19, 2024 | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmon… NCT03955146 · Idiopathic Pulmonary Fibrosis Pamrevlumab, Placebo | KYNB Kyntra Bio | Phase 3 | Terminated | 393 | Mar 20, 2023 | Registry ↗ |
| Aug 27, 2024 | Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DM… NCT02606136 · Duchenne Muscular Dystrophy Pamrevlumab | KYNB Kyntra Bio | Phase 2 | Terminated | 21 | May 7, 2020 | Registry ↗ |
| Aug 26, 2024 | Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participant… NCT04632940 · Duchenne Muscular Dystrophy Pamrevlumab, Placebo | KYNB Kyntra Bio | Phase 3 | Terminated | 73 | Jun 12, 2023 | Registry ↗ |
| Aug 12, 2024 | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fib… NCT04419558 · Idiopathic Pulmonary Fibrosis Pamrevlumab, Placebo | KYNB Kyntra Bio | Phase 3 | Terminated | 372 | Sep 4, 2023 | Registry ↗ |
| Aug 1, 2024 | Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysp… NCT03263091 · Primary MDS (Very Low, Low or Intermediate IPSS-R With <5%… Roxadustat, Placebo | KYNB Kyntra Bio | Phase 3 | Terminated | 184 | Mar 9, 2023 | Registry ↗ |
| Mar 12, 2024 | Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambu… NCT04371666 · Duchenne Muscular Dystrophy Pamrevlumab, Placebo | KYNB Kyntra Bio | Phase 3 | Terminated | 98 | Feb 13, 2023 | Registry ↗ |
| Jul 12, 2023 | Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis NCT00074698 · Idiopathic Pulmonary Fibrosis FG-3019 | KYNB Kyntra Bio | Phase 1 | Completed | 21 | — | Registry ↗ |
| Jun 6, 2023 | A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participan… NCT05301517 · Chemotherapy Induced Anemia SEPO®, Roxadustat | KYNB Kyntra Bio | Phase 3 | Completed | 159 | Apr 3, 2023 | Registry ↗ |
| May 3, 2023 | Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplas… NCT03303066 · Anemia, Myelodysplastic Syndrome FG-4592, Placebo | KYNB Kyntra Bio | Phase 2/3 | Completed | 43 | Jan 11, 2023 | Registry ↗ |
| Mar 2, 2023 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Adv… NCT02210559 · Pancreatic Cancer (Unresectable) FG-3019, Gemcitabine | KYNB Kyntra Bio | Phase 1/2 | Completed | 37 | Dec 15, 2021 | Registry ↗ |
| Sep 13, 2022 | Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (E… NCT04410198 · Anemia Associated With End Stage Renal Disease (ESRD) Roxadustat | KYNB Kyntra Bio | Phase 3 | Completed | 203 | Jun 30, 2021 | Registry ↗ |
| Jul 26, 2022 | Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment… NCT04484857 · Anemia Associated With End Stage Renal Disease Roxadustat | KYNB Kyntra Bio | Phase 3 | Completed | 283 | Jul 9, 2021 | Registry ↗ |
| Jul 18, 2022 | Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acut… NCT04432298 · COVID-19 Pamrevlumab, Placebo | KYNB Kyntra Bio | Phase 2 | Terminated | 22 | Mar 22, 2021 | Registry ↗ |
| Jul 5, 2022 | Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediat… NCT04621331 · Anemia Associated With Chronic Kidney Disease Roxadustat | KYNB Kyntra Bio | Phase 3 | Withdrawn | 0 | May 23, 2022 | Registry ↗ |
| Jun 3, 2022 | Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia NCT04076943 · Chemotherapy Induced Anemia Roxadustat | KYNB Kyntra Bio | Phase 2 | Completed | 92 | Mar 26, 2021 | Registry ↗ |
| May 6, 2022 | Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia… NCT04059913 · CKD Anemia in Dialysis Participants Roxadustat | KYNB Kyntra Bio | Phase 4 | Completed | 318 | Nov 19, 2021 | Registry ↗ |
| Feb 10, 2022 | Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia NCT01244763 · Chronic Kidney Disease, Anemia Roxadustat | KYNB Kyntra Bio | Phase 2 | Completed | 145 | Jun 13, 2012 | Registry ↗ |
| Jan 11, 2022 | Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance He… NCT01147666 · End Stage Renal Disease, Anemia Roxadustat, Epoetin Alfa | KYNB Kyntra Bio | Phase 2 | Completed | 161 | Oct 15, 2012 | Registry ↗ |
| Nov 19, 2021 | Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Di… NCT00761657 · Chronic Kidney Disease, Anemia Roxadustat, Placebo | KYNB Kyntra Bio | Phase 2 | Completed | 117 | Jun 21, 2010 | Registry ↗ |
| Oct 29, 2021 | Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants… NCT02273726 · CKD Anemia in Stable Dialysis Patients Epoetin Alfa, Roxadustat | KYNB Kyntra Bio | Phase 3 | Completed | 741 | Sep 19, 2018 | Registry ↗ |
| Oct 1, 2021 | Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Di… NCT02052310 · Anemia in Incident Dialysis Patients Roxadustat, Epoetin Alfa | KYNB Kyntra Bio | Phase 3 | Completed | 1,043 | Sep 21, 2018 | Registry ↗ |
| Oct 1, 2021 | A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and N… NCT01750190 · CKD Anemia Roxadustat, Placebo | KYNB Kyntra Bio | Phase 3 | Completed | 922 | Sep 24, 2018 | Registry ↗ |
| Oct 1, 2021 | Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With… NCT01630889 · Chronic Kidney Disease, End Stage Renal Disease Roxadustat | KYNB Kyntra Bio | Phase 2 | Completed | 15 | Dec 12, 2019 | Registry ↗ |
| Oct 1, 2021 | Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Ery… NCT01414075 · Dialysis, Anemia Roxadustat, Oral Iron | KYNB Kyntra Bio | Phase 2 | Completed | 60 | Jan 10, 2013 | Registry ↗ |
| Sep 4, 2020 | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary… NCT01890265 · Idiopathic Pulmonary Fibrosis Pamrevlumab, Placebo | KYNB Kyntra Bio | Phase 2 | Completed | 160 | Nov 16, 2017 | Registry ↗ |
| Oct 9, 2019 | Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis NCT01262001 · Idiopathic Pulmonary Fibrosis FG-3019, FG-3019 | KYNB Kyntra Bio | Phase 2 | Completed | 90 | Jun 26, 2014 | Registry ↗ |
| Aug 2, 2019 | Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropat… NCT00754143 · Diabetes Mellitus, Diabetic Nephropathy FG-3019, FG-3019 | KYNB Kyntra Bio | Phase 1 | Completed | 38 | Dec 2009 | Registry ↗ |
| Jul 31, 2019 | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomeruloscle… NCT00782561 · Focal Segmental Glomerulosclerosis FG-3019 | KYNB Kyntra Bio | Phase 1 | Terminated | 2 | Jun 18, 2009 | Registry ↗ |
| Feb 22, 2019 | Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi an… NCT00913393 · Type 2 Diabetes Mellitus, Diabetic Nephropathy FG-3019, FG-3019 | KYNB Kyntra Bio | Phase 2 | Terminated | 46 | Jun 2010 | Registry ↗ |
| Aug 24, 2017 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis NCT02652819 · Anemia FG-4592, Placebo | KYNB Kyntra Bio | Phase 3 | Completed | 154 | Jan 24, 2017 | Registry ↗ |
| Aug 24, 2017 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease NCT02652806 · Anemia FG-4592, Epoetin Alfa | KYNB Kyntra Bio | Phase 3 | Completed | 305 | Jan 24, 2017 | Registry ↗ |
| Aug 16, 2016 | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection NCT01217632 · Liver Fibrosis Due to Chronic Hepatitis B Infection FG-3019, Placebo | KYNB Kyntra Bio | Phase 2 | Terminated | 114 | Jun 2015 | Registry ↗ |
35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:38 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances